Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Gene Ther. 2008 Mar 20;15(14):1024–1034. doi: 10.1038/gt.2008.30

Figure 1.

Figure 1

(a) Cytopathic effect following MV-CEA/geldanamycin (GA) combination treatment. Addition of GA (30 nM), 24 h after infection with MV-CEA resulted in significant increase in cell fusion and cytopathic effect in different tumor cell lines (MDA-MB-231-breast; SKOV3.IP-ovarian; and TE671-rhabdomyosarcoma) as compared to virus alone. Images were obtained 48 h after MV-CEA infection. (b) MV-CEA/GA treatment at the same viral doses/concentration resulted in no cytopathic effect against nontransformed cells such as normal human dermal fibroblasts (NHDFs). (c) The syncytial area size was analyzed using NIH software. There was statistically significant increase in the syncytial area, when the measles virus infection was combined with GA treatment, as compared to measles virus infection alone (asterisk (*) denotes statistical significance).